Health
Monthly vaginal ring for HIV prevention receives positive opinion from EMA – News-Medical.Net
The International Partnership for Microbicides today welcomed a positive opinion from the European Medicines Agency on the dapivirine vaginal ring for use by cisgender women ages 18 and older in developing countries to reduce their risk of HIV-1 infection.
Reviewed by Emily Henderson, B.Sc.Jul 24 2020
The International Partnership for Microbicides (IPM) today welcomed a positive opinion from the European Medicines Agency (EMA) on the dapivirine vaginal ring for use by cisgender women ages 18 and older in developing countries to reduce their risk of HIV-1 infection. The monthly ring is the first long-acting HIV prevention product and is designed to help address women’s unmet need for new methods given the persistently high rates of HIV they face, …
